Antifungal News and Research

RSS

Innovative DNA engineering technique discovers potential functions hidden within bacterial genomes

A group of University of Illinois researchers, led by Centennial Chair Professor of the Department of Chemical and Biomolecular Engineering Huimin Zhao, has demonstrated the use of an innovative DNA engineering technique to discover potentially valuable functions hidden within bacterial genomes.

6 Dec 2013

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets.

27 Nov 2013

FDA accepts Merck's NOXAFIL IV solution NDA for priority review

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational intravenous solution formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for priority review by the U.S. Food and Drug Administration.

18 Nov 2013

Concordia University professors use funds to fight fungus and update aircraft

Thanks to new funding from the Government of Canada, two Concordia University professors just might create a greener aerospace industry and help cure fungal infections.

16 Nov 2013

PDL BioPharma closes financing transaction with Durata Therapeutics

PDL BioPharma, Inc. announced today that it closed a financing transaction with Durata Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.

6 Nov 2013

Dermatologists provide list of specific treatments, procedures not required for medical care

The American Academy of Dermatology today released its list of specific treatments and procedures related to skin health and care that are not always necessary.

29 Oct 2013

Anacor Pharmaceuticals appoints arbitrator to resolve its dispute with Valeant Pharmaceuticals

Anacor Pharmaceuticals (NASDAQ:ANAC) today announced that the arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc. (Valeant), successor in interest to Dow Pharmaceutical Sciences, Inc. (DPS), has issued an Interim Final Award in favor of Anacor, awarding Anacor $100 million in damages as well as all costs of the arbitration and reasonable attorney's fees.

18 Oct 2013

Skin infection on exposure to contaminated aquarium water is under-diagnosed, says study

A skin infection linked to exposure to contaminated water in home aquariums is frequently under-diagnosed, according to a Henry Ford Hospital study.

7 Oct 2013

Newly discovered compound could be developed as antifungal drug to treat fungal infections

On a molecular level, you have more in common with shower curtain mold or the mushrooms on your pizza than you might think. Humans and fungi share similar proteins, a biological bond that makes curing fungal infections difficult and expensive.

7 Oct 2013

Mylan Pharmaceuticals launches Voriconazole for Oral Suspension

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Voriconazole for Oral Suspension, 40 mg/mL, which is the first generic version of Pfizer's VFEND for Oral Suspension.

30 Sep 2013

Study shows how deadly Candida albicans might be rendered harmless

Candida albicans is a double agent: In most of us, it lives peacefully, but for people whose immune systems are compromised by HIV or other severe illnesses, it is frequently deadly. Now a new study from Johns Hopkins and Harvard Medical School shows how targeting a specific fungal component might turn the fungus from a lion back into a kitten.

25 Sep 2013

Microbiologist finds breakthrough herbal medicine treatment for common human fungal pathogen

A Kansas State University microbiologist has found a breakthrough herbal medicine treatment for a common human fungal pathogen that lives in almost 80 percent of people.

13 Sep 2013

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Viamet Pharmaceuticals, Inc. announced today the initiation of the phase 2 clinical program for its antifungal agent VT-1161. The initial phase 2 study is designed to evaluate the safety and efficacy of VT-1161 in the treatment of vulvovaginal candidiasis (VVC) and is being conducted at leading clinical centers in the United States.

7 Sep 2013

CorMedix's Neutrolin catheter lock solution receives CE Mark approval

CorMedix Inc. today announced that it has received CE Mark approval for Neutrolin, a catheter lock solution, for patients with central venous catheters on hemodialysis secondary to advanced chronic kidney disease.

6 Jul 2013

University of Manchester, F2G to develop new antifungal drug for fungal infections

F2G Ltd and The University of Manchester Announce a new €6.1million project to develop new antifungal agents to treat resistant fungal infections.

26 Jun 2013

Newly developed palm-sized microarray platform could enable faster, more efficient drug discovery

A new palm-sized microarray that holds 1,200 individual cultures of fungi or bacteria could enable faster, more efficient drug discovery, according to a study published in mBio-, the online open-access journal of the American Society for Microbiology.

25 Jun 2013

UT candidate wins AHA fellowship to support research in cardiovascular, stroke discoveries

University of Texas at San Antonio biomedical engineering Ph.D. candidate Anand Srinivasan has been awarded a $25,000, one-year doctoral fellowship from the American Heart Association (AHA).

20 Jun 2013

Spinal infection at contaminated drug injection site detected using contrast-enhanced MRI screening

Magnetic resonance imaging (MRI) at the site of injection of a contaminated lot of a steroid drug to treat symptoms such as back pain resulted in earlier identification of patients with probable or confirmed fungal spinal or paraspinal infection, allowing early initiation of medical and surgical treatment, according to a study in the June 19 issue of JAMA.

19 Jun 2013

Nearly 5 million asthmatics with ABPA could benefit from antifungal treatment, say researchers

An estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis (ABPA) could benefit substantially from antifungal treatment, say researchers from the University of Toronto and Manchester University.

9 May 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013